[1] Lee WM, Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away? J Hepato, 67 (6), 1324-1331 (2017).
[2] Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, Danielsson A, Sandberg-Gertzén H, Lööf L, Prytz H, Björnsson E, Acute liver failure in Sweden: etiology and outcome, J Intern Medicine, 262, 393-401 (2007).
[3] Oda S and Yokoi T, Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms, Yakugaku Zassi, 135 (4), 579-588 (2015).
[4] Licata A, Minissale MG, Calvaruso V, Craxì A, A focus on epidemiology of drug- induced liver injury: analysis of a prospective cohort, Eur Rev Med Pharmacol Sci, 21, 112-121 (2017).
[5] Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH., Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters, Mol Pharmacol, 77, 687-694 (2010).
[6] Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz DL, Association of CYP2C9*2 with Bosentan-Induced Liver Injury., Clin Pharmacol Ther, 94 (6), 1-20 (2013).
[7] Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP., Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes., Gastroenterology, 132 (1) 272-281 (2007).
[8] Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, Chen WS, SLCO1B1*15 haplotype is associated with rifampin-induced liver injury, Mol Med Rep, 6 (1) 75-82 (2012).
[9] Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, Hallberg P, Li YJ, Lucena MI, Long N, Molokhia M, Nelson MR, Odin JA, Pirmohamed M, Rafnar T, Serrano J, Stefánsson K, Stolz A, Daly AK, Aithal GP, Watkins PB, A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury, Gastroenterology, 156 (6) 1707-1716 (2019).
[10] Casado M, Mollá B, Roy R, Fernández-Martínez A, Cucarella C, Mayoral R, Boscá L, Martín-Sanz P, Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes, Hepatology, 45, 631–638 (2007).
[11] Murakami M and Kudo I, Prostaglandin E synthase: a novel drug target for inflammation and cancer, Curr Pharm Des, 12 (8), 943-954 (2006).
[12] Agins AP and Delhagen JE, Delhagen, Metabolism of prostaglandin E2 by human HL-60 leukemia cells, Agent and Action, 21, 3-4 (1987).
[13] Matsuo M, Ensor CM, Tai HH., Cloning and expression of the cDNA for mouse NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase, Biochim Biolphys Acta., 1309, 21-24 (1996).
[14] Ivanov AI, Scheck AC, Romanovsky AA., Expression of genes controlling transport and catabolism of prostaglandin E2 in lipopolysaccharide fever, Am J Physiol Regul Integr Comp Physiol, 284, R698-706 (2003).
[15] Mitchell MD, Goodwin V, Mesnage S, Keelan JA, Cytokine-induced coordinate expression of enzymes of prostaglandin biosynthesis and metabolism: 15- hydroxyprostaglandin dehydrogenase, Prostaglandins Leukot Essent Fatty Acids, 62(1), 1-5 (2000)
[16] Miyaki A, Yang P, Tai HH, Subbaramaiah K, Dannenberg AJ., Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes, Am J Physiol Gastrointest Liver Physiol, 297 (3), G559-566 (2009).
[17] Bito LZ and Baroody RA., Impermeability of rabbit erythrocytes to prostaglandins, Am J Physiol, 229, 1580-1584 (1975).
[18] Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL, Identification and characterization of a prostaglandin transporter, Science, 268, 866-869 (1995).
[19] Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji AT, Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family, Biochem Biophys Res Commun, 273, 251-260 (2000).
[20] Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H., Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins., J Pharmacol Exp Ther, 301, 293-298 (2002).
[21] Shiraya K, Hirata T, Hatano R, Nagamori S, Wiriyasermkul P, Jutabha P, Matsubara M, Muto S, Tanaka H, Asano S, Anzai N, Endou H, Yamada A, Sakurai H, Kanai Y., A novel transporter of SLC22 family specifically transports prostaglandins and co- localizes with 15-hydroxyprostaglandin dehydrogenase in renal proximal tubules, J Biol Chem, 285, 22141-22251 (2010).
[22] Kobayashi Y, Nojima J, Ohbayashi M, Kohyama N, Yamamoto T., Molecular cloning and functional characterization of a novel gene encoding human prostaglandin carrier, hPrC, Yakugaku Zasshi, 131, 1493-1501 (2011).
[23] de Waart DR, Paulusma CC, Kunne C, Oude Elferink RP, Multidrug resistance associated protein 2 mediates transport of prostaglandin E2, Liver Int, 26, 362-368 (2006).
[24] Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P, The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs, Proc Natl Acad Sci USA, 100, 9244-9249 (2003).
[25] Chan BS, Satriano JA, Pucci M, Schuster VL., Mechanism of Prostaglandin E2 Transport across the Plasma Membrane of HeLa Cells and Xenopus Oocytes Expressing the Prostaglandin Transporter “PGT”, J Biol Chem, 273, 6689–6697 (1998).
[26] Shimada H, Nakamura Y, Nakanishi T, Tamai I., OATP2A1/SLCO2A1-mediated prostaglandin E2 loading into intracellular acidic compartments of macrophages contributes to exocytotic secretion, Biochem Pharmacol, 98, 629-638 (2015).
[27] Nakanishi T, Hasegawa Y, Mimura R, Wakayama T, Uetoko Y, Komori H, Akanuma S, Hosoya K, Tamai., Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis, PLoS One, 10 (4), e0123895, (2015).
[28] Zhang Z, Xia W, He J, Zhang Z, Ke Y, Yue H, Wang C, Zhang H, Gu J, Hu W, Fu W, Hu Y, Li M, Liu Y., Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy, Am J Hum Genet, 90, 125-132 (2012).
[29] Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH, Langenbach R, Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2, Proc Natl Sci USA, 98, 1059- 1064 (2001).
[30] Xiao J, Liong EC, Huang H, On Tse W, Lau KS, Pan J, Nanji AA, Fung M, Xing F, Tipoe GL, Cyclooxygenase-1 serves a vital hepato-protective function in chemically induced acute liver injury, Toxicol Sci, 143, 430-440 (2015).
[31] Stachura J, Tarnawski A, Ivey KJ, Mach T, Bogdal J, Szczudrawa J, klimczyk B., Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat, Gastroenterology, 81(2), 211-217 (1981).
[32] Kuzumoto Y, Sho M, Ikeda N, Hamada K, Mizuno T, Akashi S, Tsurui Y, Kashizuka H, Nomi T, Kubo A, Kanehiro H, Nakajima Y, Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice., Hepatology, 42 (3), 608-617 (2005).
[33] Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T, Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury, Toxicol Sci, 130, 4-16 (2012).
[34] Dawson W, Jessup SJ, McDonald-Gibson W, Ramwell PW, Shaw JE, Prostaglandin uptake and metabolism by the perfused rat liver, Br J Pharmaco, 39 (3), 585-598 (1970).
[35] Khan RA, Khan MR, Sahreen S., CCl4-induced hepatotoxicity: protective effect of rutin on p53, CYP2E1 and the antioxidative status in rat, BMC Complement Altern. Med, 12, 178 (2012).
[36] Liu C, Tao Q, Sun M, Wu JZ, Yang W, Jian P, Peng J, Hu Y, Liu C, Liu P, Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats, Lab. Invest, 90, 1805-1816 (2010).
[37] Kiso K, Ueno S, Fukuda M, Ichi I, Kobayashi K, Sakai T, Fukui K, Kojo S, The role of Kupffer cells in carbon tetrachloride intoxication in mice, Biol Pharm Bull, 35, 980-983 (2012)
[38] Ekor M, Odewabi AO, Kale OE, Adesanoye OA, Bamidele TO, Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats, Drug Chem Toxicol, 36 (1), 1-8 (2013).
[39] Zhang Y, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, Tiwari S, Willis JE, Williams NS, Dawson DM, Wald D, Chen WD, Wang Z, Kasturi L, Larusch GA, He L, Cominelli F, Di Martino L, Djuric Z, Milne GL, Chance M, Sanabria J, Dealwis C, Mikkola D, Naidoo J, Wei S, Tai HH, Gerson SL, Ready JM, Posner B, Willson JK, Markowitz SD, TISSUE REGENERATION, Inhibition of the prostaglandin- degrading enzyme 15-PGDH potentiates tissue regeneration, Science, 348 (6240) : aaa2340 (2015).
[40] Nakamura Y, Nakanishi T, Shimada H, Shimizu J, Aotani R, Maruyama S, Higuchi K, Okura T, Deguchi Y, Tamai I., Prostaglandin Transporter OATP2A1/SLCO2A1 Is Essential for Body Temperature Regulation during Fever, J Neurosci, 38 (24), 5584-5595 (2018).
[41] Hidalgo GE, Zhong L, Doherty DE, Hirschowitz EA, Plasma PGE2 levels and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC), Mol Cancer, 1: 5 (2002).
[42] Piper PJ, Vane JR, Wyllie JH., Inactivation of prostaglandins by the lungs, Nature, 225 (5233), 600-604 (1970).
[43] Schepers L, Casteels M, Vamecq J, Parmentier G, Van Veldhoven PP, Mannaerts GP., Beta-oxidation of the carboxyl side chain of prostaglandin E2 in rat liver peroxisomes and mitochondria, J Biol Chem, 263 (6), 2724-2731 (1988).
[44] Bylund J, Hidestrand M, Ingelman-Sundberg M, Oliw EH, Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides., J Biol Chem, 275 (29) 21844-21849 (2000).
[45] Roberts HR, Smartt HJ, Greenhough A, Moore AE, Williams AC, Paraskeva C., Colon tumour cells increase PGE (2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation, Carcinogenesis, 32 (11), 1741-1747 (2011).
[46] Hughes D, Otani T, Yang P, Newman RA, Yantiss RK, Altorki NK, Port JL, Yan M, Markowitz SD, Mazumdar M, Tai HH, Subbaramaiah K, Dannenberg AJ, NAD+- dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer, Cancer Prev Res (Phila), 1 (4) 241-249 (2008).
[47] Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, Tai HH, Monni O, Kokkola A, Haglund C, Petrova TV, Ristimäki A, 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer, Clin Cancer Res, 15 (14), 4572- 4580 (2009).
[48] Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D., Cyclooxygenase in normal human tissues--is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med, 13 (9B), 3753-3763 (2009).
[49] Johnston DE and Kroening C., Stimulation of prostaglandin synthesis in cultured liver cells by CCl4, Hepatology, 24, 677-684(1996).
[50] Hashimoto N, Watanabe T, Shiratori Y, Ikeda Y, Kato H, Han K, Yamada H, Toda G, Kurokawa K, Prostanoid secretion by rat hepatic sinusoidal endothelial cells and its regulation by exogenous adenosine triphosphate, Hepatology, 21, 1713-1718 (1995).
[51] Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H., Expression cloning and characterization of a novel multispecific organic anion transporter, J Biol Chem, 272 (30), 18526-18529 (1997).
[52] Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manautou JE, Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride, Toxicol Sci, 83 (1) 44-52 (2005).
[53] Nakanishi T, Ohno Y, Aotani R, Maruyama S, Shimada H, Kamo S, Oshima H, Oshima M, Schuetz JD, Tamai I, A novel role for OATP2A1/SLCO2A1 in a murine model of colon cancer, Sci Rep, 7, 16567 (2017).
[54] Lertratanangkoon K. Horning MG, Horning, Metabolism of carbamazepine, Drug Metab Dispos, 10, 1-10 (1982).
[55] Bertilsson L, Tomson T., Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide, An update, Clin Pharmacokinet, 11, 177-198 (1986).
[56] Lu W, Uetrecht JP., Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin, Drug Metab Dispos, 36, 1624-1636 (2008).
[57] Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK., An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro, Biochem Pharmacol, 43, 1675-1682 (1992).
[58] Iida A, Sasaki E, Yano A, Tsuneyama K, Fukami T, Nakajima M, Yokoi T., Carbamazepine-Induced Liver Injury Requires CYP3A-Mediated Metabolism and Glutathione Depletion in Rats, Drug Metab Dispos, 43, 958-968 (2015).
[59] Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK., Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity, Br J Clin Pharmacol, 33, 183-186 (1992).
[60] Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F, Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain, Biol Psychiatry, 56, 248-254 (2004).
[61] Nassar A, Sharon-Granit Y, Azab AN., Psychotropic drugs attenuate lipopolysaccharide-induced hypothermia by altering hypothalamic levels of inflammatory mediators in rats, Neurosci Lett, 626, 59-67 (2016).
[62] Tsujii H, Okamoto Y, Kikuchi E, Matsumoto M, Nakano H, Prostaglandin E2 and rat liver regeneration, Gastroenterology, 105, 495-499 (1993).
[63] Lin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, McGrath J, Waxman SG, Sartorelli AC., Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response., Mol Pharmacol, 73, 243-251 (2008).
[64] Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD., Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice, J Biol Chem, 279, 22250-22257 (2004).
[65] Chai J, Luo D, Wu X, Wang H, He Y, Li Q, Zhang Y, Chen L, Peng ZH, Xiao T, Wang R, Chen W, Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis, J Gastrointest Surg, 15, 996-1004 (2011).
[66] Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL, Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat, J Hepatol, 40 (4) 585-591 (2004).
[67] Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 320, 72-80 (2007).
[68] Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 30, 795-804 (2002).
[69] Cheng X, Maher J, Dieter MZ, Klaassen CD, Regulation of mouse organic anion- transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways, Drug Metab Dispos, 33, 1276-1282 (2005).
[70] Gose T, Nakanishi T, Kamo S, Shimada H, Otake K, Tamai I, Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid- derived PGE3, Prostaglandins Other Lipid Mediat, 122, 10- 17 (2016).
[71] Pucci ML, Chakkalakkal B, Liclican EL, Leedom AJ, Schuster VL, Abraham NG. Augmented heme oxygenase-1 induces prostaglandin uptake via the prostaglandin transporter in micro-vascular endothelial cells. Biochem Biophys Res Commun, 323, 1299-1305 (2004)
[72] Nakahira K, Takahashi T, Shimizu H, Maeshima K, Uehara K, Fujii H, Nakatsuka H, Yokoyama M, Akagi R, Morita K. Protective role of heme oxygenase-1 induction in carbon tetrachloride-induced hepatotoxicity, Biochem Pharmacol, 66, 1091-1105 (2003).
論文の公開元へ
